COMP <GO>
OABI vs ABBV // DIVIDEND YIELD & FCF PAYOUT SAFETY
OmniAb Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: OABI 1
— ABBV 9
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: ABBV
LAST: $5.23 (-0.95%) • MKT CAP: $760.4M
dividend-safety
0.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
dividend-safety
2.27%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OABI VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OABI | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -22.60% | 29.00% | -51.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.87% | 3.47% | -8.34 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -29.30% | 8.60% | -37.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.19 | 5.33 | +6.86 | OABI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 7/9 | -5.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.7 | 65.1 | -6.43 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $760.4M | $513.86B | -$513.10B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OABI REV | ABBV REV | OABI GROSS % | ABBV GROSS % | OABI FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $18.7M | $61.16B | — | 70.2% | -$37.0M | $17.82B |
| FY 2024 | $26.4M | $56.33B | — | 70.0% | -$41.5M | $17.83B |
| FY 2023 | $34.2M | $54.32B | — | — | $2.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OABI // BETA —
ABBV // BETA 1.15